Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
None AUD 0.00(0%)
Last update at 2026-11-12T06:45:02.945118Z
Market Cap
0.54M

Momentum Score

…

Hexima Limited does not have significant operations. It focuses on exploration of transactions with third parties, which could enable the value of the company's assets. Previously, the company was involved in the research and development of plant-derived proteins for applications as human therapeutics. The company was incorporated in 1997 and is based in Carlton, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.01
Low
0.05
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Hexima Limited is an Australian life sciences company developing plant-derived peptide technologies for crop protection and human health applications. Its long-term growth may be driven by successful R&D outcomes, commercialization or licensing of its intellectual property and wider industry adoption of peptide-based solutions. Investors may find the company attractive for its differentiated platform and potential to generate scalable licensing and product revenues if development milestones are met.
Primary investment risks include early-stage development status with limited commercial revenue, reliance on successful trials and partner or license agreements, ongoing funding needs, and competition from larger biotech and agrochemical firms.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.05
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-25.53%
Net Debt
-1.54M
ROCE
-111.52%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Income before tax -0.22M -0.50M -0.50M -1.00M -1.00M
Net income -0.22M -0.50M -0.50M -0.93M -0.93M
Selling general administrative 0.23M 0.23M 0.23M 0.29M 0.29M
Selling and marketing expenses - 0.06M 0.06M 0.26M 0.26M
Ebit -0.26M - - -1.01M -1.01M
Ebitda -0.26M - - -1.00M -1.00M
Depreciation and amortization - 0.32M 0.32M 0.01M 0.01M
Operating income -0.26M -0.29M -0.29M -1.01M -1.01M
Other operating expenses - 0.29M 0.29M 1.01M 1.01M
Tax provision 0.00M - 0.00M 0.00M 0.00M
Interest income 0.04M - 0.05M 0.04M 0.04M
Net interest income 0.04M - - 0.04M 0.04M
Income tax expense - - - -0.06M -0.06M
Total revenue - - 0.00M - 0.06M
Total operating expenses - 0.29M 0.29M 1.01M 1.01M
Total other income expense net -0.00M -0.22M -0.22M 0.01M 0.01M
Net income from continuing ops -0.22M - - -0.93M -0.93M
Net income applicable to common shares - - -0.50M - -0.93M
Breakdown 2026-06-30 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Total assets 0.28M 1.56M 1.56M 2.27M 2.27M
Other current assets - 0.01M 0.01M - -
Total liab 0.04M 0.04M 0.04M 0.25M 0.25M
Total stockholder equity 0.24M 1.52M 1.52M 2.02M 2.02M
Other current liab - 0.03M 0.03M 0.14M 0.14M
Common stock - 82.88M 82.88M 82.88M 82.88M
Capital stock 81.82M - - 82.88M -
Retained earnings -82.67M -82.44M -82.44M -81.95M -81.95M
Cash 0.26M 1.54M 1.54M 2.23M 2.23M
Total current liabilities 0.04M 0.04M 0.04M 0.25M 0.25M
Net debt - -1.54M -1.54M -2.23M -2.23M
Total current assets 0.28M 1.56M 1.56M 2.27M 2.27M
Net receivables - 0.01M 0.01M 0.04M 0.04M
Accounts payable 0.01M 0.01M 0.01M 0.11M 0.11M
Accumulated other comprehensive income - 1.08M 1.08M 1.09M 1.09M
Non current assets total 0.00M - - 0.00M -
Breakdown 2026-06-30 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Investments - - - - 0.14M
Total cashflows from investing activities - 0.05M 0.05M 0.10M 0.10M
Total cash from financing activities -1.06M -0.10M -0.10M 0.10M 0.10M
Net income -0.22M -0.50M -0.50M -0.93M -0.93M
Change in cash -1.28M -0.69M -0.69M 0.04M 0.04M
Begin period cash flow 1.54M 2.23M 2.23M 2.19M 2.19M
End period cash flow 0.26M 1.54M 1.54M 2.23M 2.23M
Total cash from operating activities - -0.64M -0.64M -0.16M -0.16M
Other cashflows from investing activities - 0.05M 0.05M 0.10M 0.10M
Change to account receivables - 0.02M 0.02M 0.63M 0.63M
Sale purchase of stock -1.06M - - - 0.10M
Other cashflows from financing activities - -0.10M -0.10M 0.10M 0.10M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital - 0.02M 0.02M 0.63M 0.63M
Other non cash items - -0.15M -0.15M -0.79M -0.79M
Free cash flow -0.27M -0.64M -0.64M -0.16M -0.16M

Peer Comparison*

Sector: Financial Services Industry: Shell Companies

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)

Profile*

Hexima Limited.

Hexima Limited does not have significant operations. It focuses on exploration of transactions with third parties, which could enable the value of the company's assets. Previously, the company was involved in the research and development of plant-derived proteins for applications as human therapeutics. The company was incorporated in 1997 and is based in Carlton, Australia.

C/-Acclime, Carlton, VIC, Australia, 3053

61 3 9824 5254

Name Title Year Born
Dr. Nicole van der Weerden B.Sc., BSc (Hons), MBA (MBS), Ph.D. Acting CEO, COO & Exec. Director NA
Ms. Helen Molloy Financial Controller NA
Prof. Marilyn A. Anderson A.O., AO, B.Sc., BSc (Hons), FAA, FAICD, FT Chief Science Officer 1951
Dr. Nancy Sacco Chief Devel. Officer NA
Ms. Leanne Ralph Company Sec. NA
Dr. Neil Forrester VP of Bus. Devel. NA
Prof. Adrienne Elizabeth Clarke Science Advisor 1938
Dr. Nancy Sacco Chief Development Officer NA
Dr. Nancy Sacco Chief Development Officer NA
Mr. Geoffrey Paul Kempler B.Sc. MD & Chairman 1955

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…